Clinicians' guide to microarrays

L Maraqa; C F Donnellan; M B Peter; V Speirs

doi:10.1016/j.suronc.2006.12.003

Clinicians' guide to microarrays

L Maraqa
, C F Donnellan
, M B Peter
, V Speirs

St James's University Hospital

Research output: Contribution to journal › Review article › peer-review

4 Citations (Scopus)

Abstract

Cancer is a heterogeneous disease with wide-ranging subsets of patients who have different prognoses and who respond differently to treatments. Accordingly, deciding the best treatment strategy has become a priority in cancer care. The development of microarray technology over the last decade has caused great excitement, with the promise that these new tools may provide molecular signatures to help predict patient outcome and direct therapeutic approaches. Here, we describe the different types of microarrays available and discuss their pros and cons from a clinical perspective, with respect to breast cancer.

Original language	English
Pages (from-to)	205-10
Number of pages	6
Journal	Surgical Oncology
Volume	15
Issue number	4
DOIs	https://doi.org/10.1016/j.suronc.2006.12.003
Publication status	Published - Dec 2006
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Biomarkers, Tumor
Gene Expression
Humans
Neoplasms
Oligonucleotide Array Sequence Analysis
Prognosis
RNA, Neoplasm
Treatment Outcome
Journal Article
Research Support, Non-U.S. Gov't
Review

Access to Document

10.1016/j.suronc.2006.12.003

Cite this

@article{e9c9f7117c404596add2b9252ae142de,

title = "Clinicians' guide to microarrays",

abstract = "Cancer is a heterogeneous disease with wide-ranging subsets of patients who have different prognoses and who respond differently to treatments. Accordingly, deciding the best treatment strategy has become a priority in cancer care. The development of microarray technology over the last decade has caused great excitement, with the promise that these new tools may provide molecular signatures to help predict patient outcome and direct therapeutic approaches. Here, we describe the different types of microarrays available and discuss their pros and cons from a clinical perspective, with respect to breast cancer.",

keywords = "Biomarkers, Tumor, Gene Expression, Humans, Neoplasms, Oligonucleotide Array Sequence Analysis, Prognosis, RNA, Neoplasm, Treatment Outcome, Journal Article, Research Support, Non-U.S. Gov't, Review",

author = "L Maraqa and Donnellan, \{C F\} and Peter, \{M B\} and V Speirs",

year = "2006",

month = dec,

doi = "10.1016/j.suronc.2006.12.003",

language = "English",

volume = "15",

pages = "205--10",

journal = "Surgical Oncology",

issn = "0960-7404",

publisher = "Elsevier Limited",

number = "4",

}

TY - JOUR

T1 - Clinicians' guide to microarrays

AU - Maraqa, L

AU - Donnellan, C F

AU - Peter, M B

AU - Speirs, V

PY - 2006/12

Y1 - 2006/12

N2 - Cancer is a heterogeneous disease with wide-ranging subsets of patients who have different prognoses and who respond differently to treatments. Accordingly, deciding the best treatment strategy has become a priority in cancer care. The development of microarray technology over the last decade has caused great excitement, with the promise that these new tools may provide molecular signatures to help predict patient outcome and direct therapeutic approaches. Here, we describe the different types of microarrays available and discuss their pros and cons from a clinical perspective, with respect to breast cancer.

AB - Cancer is a heterogeneous disease with wide-ranging subsets of patients who have different prognoses and who respond differently to treatments. Accordingly, deciding the best treatment strategy has become a priority in cancer care. The development of microarray technology over the last decade has caused great excitement, with the promise that these new tools may provide molecular signatures to help predict patient outcome and direct therapeutic approaches. Here, we describe the different types of microarrays available and discuss their pros and cons from a clinical perspective, with respect to breast cancer.

KW - Biomarkers, Tumor

KW - Gene Expression

KW - Humans

KW - Neoplasms

KW - Oligonucleotide Array Sequence Analysis

KW - Prognosis

KW - RNA, Neoplasm

KW - Treatment Outcome

KW - Journal Article

KW - Research Support, Non-U.S. Gov't

KW - Review

U2 - 10.1016/j.suronc.2006.12.003

DO - 10.1016/j.suronc.2006.12.003

M3 - Review article

C2 - 17291747

SN - 0960-7404

VL - 15

SP - 205

EP - 210

JO - Surgical Oncology

JF - Surgical Oncology

IS - 4

ER -

Clinicians' guide to microarrays

Abstract

UN SDGs

Keywords

Access to Document

Fingerprint

Cite this